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ABSTRACT
Human artificial chromosome (HAC)-based vectors
represent an alternative technology for gene deliv-
ery and expression with a potential to overcome
the problems caused by virus-based vectors. The
recently developed alphoidtetO-HAC has an advan-
tage over other HAC vectors because it can be eas-
ily eliminated from cells by inactivation of the HAC
kinetochore via binding of chromatin modifiers, tTA
or tTS, to its centromeric tetO sequences. This pro-
vides a unique control for phenotypes induced by
genes loaded into the HAC. The alphoidtetO-HAC elim-
ination is highly efficient when a high level of chro-
matin modifiers as tetR fusion proteins is achieved
following transfection of cells by a retrovirus vector.
However, such vectors are potentially mutagenic and
might want to be avoided under some circumstances.
Here, we describe a novel system that allows verifi-
cation of phenotypic changes attributed to expres-
sion of genes from the HAC without a transfection
step. We demonstrated that a single copy of tTAVP64
carrying four tandem repeats of the VP16 domain
constitutively expressed from the HAC is capable to
generate chromatin changes in the HAC kinetochore
that are not compatible with its function. To adopt
the alphoidtetO-HAC for routine gene function stud-
ies, we constructed a new TAR-BRV- tTAVP64 cloning
vector that allows a selective isolation of a gene of
interest from genomic DNA in yeast followed by its
direct transfer to bacterial cells and subsequent load-
ing into the loxP site of the alphoidtetO-HAC in ham-
ster CHO cells from where the HAC may be MMCT-
transferred to the recipient human cells.
INTRODUCTION
Human artificial chromosomes or HAC-based vectors rep-
resent a novel system for gene delivery and expression that
has several advantages over previous gene and cell therapy
strategies (1–4). All HACs by definition contain a func-
tional centromere and, therefore, replicate and segregate
like normal chromosomes in human cells without integra-
tion into the host genome. HAC vectors are essentially lim-
ited only by our ability to generate and handle large DNA
fragments, and therefore, may provide long-term expression
of complete genetic loci. Several labs succeeded in comple-
mentation of gene deficiencies in human recipient cell lines
and in creation of the transgenic mice using HAC vectors
containing genomic copies of genes with all their regulatory
elements, demonstrating their potential as therapeutic gene
expression vectors (5–26).
HACs can be engineered by ‘top-down’ or ‘bottom-up’
(de novo formation) approaches (1–4,27,28). The top-down
approach is based on telomere-associated chromosome
fragmentation in the homologous recombination-proficient
chicken DT40 cell line. The bottom-up approach includes
transfection of human cells with either natural or synthetic
alpha-satellite (alphoid)DNAarrays with a size bigger than
30 kb. After transfection of such arrays into human cells, de
novoHACs are generated that range in size from 1Mb to 10
Mb due to concatemerization of input constructs and am-
plification of alphoid DNA.
One of the most advanced HACs is the alphoidtetO-HAC,
engineered using a 40 kb synthetic alphoid DNA array
(29). This array contains 42-bp tetracycline operator (tetO)
sequences incorporated into every second alphoid DNA
monomer. After multimerization of the input DNA in hu-
man cells, the resulting alphoidtetO-HAC contains ∼6000
copies of the tetO sequence within the 1.1 mega-base size
block of synthetic alphoid DNA (30). Because tetO se-
quences are bound with high affinity and specificity by the
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tet repressor (tetR), they can be targeted efficiently in vivo
with tetR fusion proteins. The power of this system is that it
allows for specific manipulation of the chromatin composi-
tion of a HAC kinetochore in vivo, while leaving all kineto-
chores of the natural chromosomes unperturbed. Targeting
of chromatin-modifying proteins into theHACkinetochore
demonstrated that a balance between open and condensed
chromatin is critical for kinetochore function (31–34). The
frequency of HAC loss was very high when either transcrip-
tionally competent or repressive chromatin was induced in
the HAC via the tTA (tet-repressor transcriptional acti-
vator containing VP16 domain) (35) or tTS (tet-repressor
transcriptional silencer - this contains the KRAB-AB do-
main of the SDkid-1 protein) (36). Tethering these chromatin
modifiers caused a block of CENP-A loading and strip-
ping of other proteins of the CCAN complex (the constitu-
tive centromere-associated network) from the HAC kineto-
chore. As a consequence, the functionalHACkinetochore is
inactivated and the HAC is lost during cell division (29,31–
34,37).
The alphoidtetO-HACwith a regulated kinetochore repre-
sents a powerful system for gene function analysis because
it provides a unique possibility to compare the phenotypes
of target human cells with and without a functional copy
of a gene inserted into the HAC. Such a rigorous control
is required for proper interpretation of gene complementa-
tion studies. The power of this system was recently demon-
strated in experiments for expression of three human full-
length genes, VHL (∼25 kb), NBS1 (∼60 kb), HPRT (∼60
kb) and BRCA1 (90 kb) from the alphoidtetO-HAC vector
transferred in patient-derived cell lines (23,38,39).
The alphoidtetO-HAC elimination bymodification of cen-
tromeric chromatin is highly efficient using either retrovirus
or plasmid-induced expression to provide a high level of
chromatin modifiers as tetR fusion proteins. Thus, inacti-
vation of the HAC kinetochore includes a transfection step
that is potentially mutagenic. Recently, we described an ap-
proach to re-engineering the alphoidtetO-HAC that allows
verification of phenotypic changes attributed to expression
of genes from the HAC without a transfection step (40). In
this alphoidtetO-HAC vector, a tTS-containing cassette was
inserted into a gene-loading site along with a gene of in-
terest. A relatively low level of expression of the tTS does
not inactivate the HAC kinetochore but generates a self-
regulating fluctuating heterochromatin on the alphoidtetO-
HAC that induces fast silencing of the genes on the HAC
without significant effects on HAC segregation. This silenc-
ing of the HAC-encoded genes can be recovered by simply
adding a ligand (doxycycline). While the alphoidtetO-HAC
vector carrying a single copy of tTS provides a simpleway to
verify phenotypic changes attributed to expression of genes
from the HAC, persistence of the HAC with a silenced gene
in cells might want to be avoided under some circumstances.
For example, this is specifically required when theHAC vec-
tor is used for generation of iPS cells (3,4,41).
In this paper, we examined whether a single copy of a
chromatin modifier, either the transcriptional transactiva-
tor tTA carrying the VP16 domain or the advanced tran-
scriptional transactivator tTAVP64 carrying four tandem re-
peats of theVP16 domain (36), inserted into the alphoidtetO-
HAC is enough to inactivate the HAC kinetochore. We
demonstrated that tTAVP64 constitutively expressed from
the HAC induces a fast inactivation of the HAC kineto-
chore leading to HAC loss. This feature of the alphoidtetO-
HAC carrying tTAVP64 is consistent with its potential broad
use in gene function studies and cell reprogramming.
One advantage of HAC-based technologies is the op-
portunity to work with full-length genes. Transformation-
associated recombination (TAR) cloning allows selective
isolation of any desired allele of a gene of interest as a pre-
determined large chromosomal fragment in yeast (42–44).
Based on our observation that a single copy transgene en-
coding a potent chromatin modifier may inactivate a kine-
tochore, we constructed a new vector, TAR-BRV- tTAVP64
that links the gene isolation strategy with the regulated gene
expression in the alphoidtetO-HAC.
MATERIALS AND METHODS
Construction of the tTA-containing plasmids, tetR-VP64-
IRES-DsRed2 and tetR*-VP16-IRES-DsRed2
The transgene cassette tetR-VP64-IRES-DsRed2 was as-
sembled as follows. The plasmid 264-CAG-IRES-DsRed
(40) was digested with PacI/NheI, then was gel puri-
fied to remove a short (∼200 bp) fragment. Next, the
tetR-NLS sequence (with complete NLS) was polymerase
chain reaction (PCR) amplified from the plasmid 264-
CAG-OKS-EF1-tTKRAB-DsRed-pA (kindly provided by
Dr. Tomilin, Institute of Cytology, RAS, Russia) with
a pair of specific primers PacI-tetR-EYFP-VP16/NheI-
NLSrev (Supplementary Table S1). Then the tetR-NLS
fragment was gel purified, digested by PacI/NheI and lig-
ated with the 264-CAG-IRES-DsRed plasmid digested by
PacI/NheI, producing the intermediate plasmid 264-CAG-
tetR-newNLS- completeIRES-DsRed. Next, this plasmid
was digested by NheI/AsiSI to insert the VP64 sequence.
The VP64 PCR sequence (carrying four copies of a sub-
section of the VP16 domain) was PCR amplified from
the Cas9D10AH840A TagBFP VP64 plasmid (kindly pro-
vided by Dr. Kagansky, Edinburgh University, Scotland)
with a pair of specific primers NheI-VP64for/ AsiSI-
VP64rev (Supplementary Table S1). The VP64 PCR frag-
ment was gel purified, digested with NheI/AsiSI and then
ligated with the 264-CAG-tetR-newNLS-completeIRES-
DsRed plasmid digested by NheI/AsiSI, producing the fi-
nal plasmid tetR-VP64-IRES-DsRed2. The transgene cas-
sette tetR*-VP16-IRES-DsRed2 was assembled similarly
except it contains only one copy of the VP16 domain.
Both plasmids contain the 3’HPRT-loxP cassette that al-
lows their insertion into the single loxP loading site of
the alphoidtetO-HAC propagated in HPRT-minus hamster
CHO or human HT1080 cells followed by reconstitution of
theHPRT gene (45,46). Detailed physical maps of the tetR-
VP64-IRES-DsRed2 and tetR*-VP16-IRES-DsRed2 plas-
mids are shown in Supplementary Figures S1 and S2a.
Construction of the TAR-BRV-tTAVP64 vector
The construction of the TAR-BRV- tTAVP64 vector was
shown in detail in Supplementary Figure S3. Steps 1–4 re-
moved restriction sites XmaI, EcoRI, BglII and XbaI from
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the pBeloBAC11 plasmid backbone (New England Bio-
labs). This was carried out as follows. Step 1: The plasmid
pBeloBAC11 was PCR amplified with a pair of primers
B161/B196 (Supplementary Table S1). PCR product was
then blunt end ligated to form plasmid A096. Step 2:
Plasmid A096 was PCR amplified with a pair of primers
B244/B245 (Supplementary Table S1). The PCR product
was then blunt end ligated to produce the intermediate plas-
mid A098. Step 3: Plasmid A098 was PCR amplified with
a pair of primers B246/B247 (Supplementary Table S1).
The PCR product was then blunt end ligated to produce
the intermediate plasmid A099. Step 4: Plasmid A099 was
PCR amplified with a pair of primers B248/B249 (Supple-
mentary Table S1). The PCR product was then blunt end
ligated to produce the intermediate plasmid A102. Step 5:
The TAR plasmid pVC604 (22) was PCR amplified with
a pair of primers B288/B287 (Supplementary Table S1).
The PCR product was then blunt end ligated to produce
the intermediate plasmid A106. This step removed restric-
tion sites BglII, NheI, BclI and HindIII sites in the HIS3
gene of pVC604. Step 6: Then three fragments were lig-
ated as follows. The first fragment, CEN6-HIS3, was PCR
amplified from A106 with a pair of primers B286/B295
(Supplementary Table S1). This fragment was then di-
gested with XhoI/BamHI. The second fragment, ARSH4,
was PCR amplified from the plasmid pRS313 (47) using
a pair of primers B294/B293 (Supplementary Table S1).
The ARSH4 fragment was then digested with SalI/XbaI.
The third fragment was amplified from the plasmid A102
using a pair of primers B022/B280 (Supplementary Table
S1) and then digested with NheI/BamHI. All three frag-
ments were then ligated to produce the intermediate plas-
mid A116. Step 7: The plasmid A116 was PCR amplified
using a pair of primers B433/B432 (Supplementary Table
S1). The PCR product was then digested with MluI and
ligated to produce the intermediate plasmid A152. This
step removed the ARSH4 segment and added MluI and
PacI sites to the plasmid. Step 8: This step included liga-
tion of two fragments. The first fragment, 3’HPRT (2256
bp in length) was obtained by digestion of the plasmid p264
(37) with XbaI/AscI. The second fragment was obtained by
PCR amplification of pBluescript II KS (Stratagene) with a
pair of primers B630/B631 (Supplementary Table S1). The
B630 primer carries with it the loxP site. The PCR prod-
uct was subsequently digested with NheI/MluI. Both frag-
ments were then ligated to produce the intermediate plas-
mid A151. Step 9: The plasmid A153 was then digested
with NheI/BamHI, while the plasmid A151 was digested
with BglII/SpeI. Both fragments were then ligated to pro-
duce the intermediate plasmid A153. Step 10: This step was
a single five-way ligation. The first fragment was obtained
by PCR amplification of the plasmid pBlueScript II SK
(Stratagene) with a pair of primers B489/B688 (Supplemen-
tary Table S1). This 2868 bp fragment was then digested
with MluI/SacI. The second fragment, tDNA-CAG (2097
bp in length), was obtained by digesting the plasmid CAG-
EGFP-tDNA (25,48) with SacI/XbaI digest. The third
fragment, CAG intron (129 bp in length), was obtained by
PCR amplification of the p264 plasmid (37) with a pair of
primers B510/B509 (Supplementary Table S1). This frag-
ment was then digested with SpeI/EcoRI. The forth frag-
ment, tetR-VP64 (842 bp in length), was obtained by PCR
amplification of the plasmid tetR-VP64-IRES-DsRed2 (see
above) with a pair of primers B487/B486 (Supplementary
Table S1). This fragment was digested with EcoRI/BglII.
The fifth fragment, SV40pA (240 bp in length), was PCR
amplified from the plasmidBRV1 (49) with a pair of primers
B619/B618 (Supplementary Table S1). This fragment was
then digested with BamHI/MluI. All five fragments were
ligated together in a single five-way ligation to produce the
intermediate plasmid A185. Step 11: This step was a sin-
gle two-way ligation. The first fragment, tDNA-CAG-tetR-
VP64 (3314 bp in length), was obtained by digesting the
plasmid A185 with AsiSI/MluI. The second fragment was
obtained by digesting the plasmid A153 with MluI/PacI.
Ligation of both fragments produced the final TAR-BRV-
tTAVP64 vector. A detailed physical map of the TAR-BRV-
tTAVP64 plasmid is shown in Supplementary Figure S5.
Cell lines and media
The hypoxanthine phosphoribosyltransferase (HPRT)-
deficient fibrosarcoma HT1080 cell line was obtained from
Dr. Zoia L. Monaco (Wellcome Trust Centre for Hu-
man Genetics, University of Oxford, Roosevelt Drive, Ox-
ford OX3 7BN, UK). The cells were cultured in Dul-
becco’s modified Eagle’s medium (DMEM) (Invitrogen)
supplemented with 10% (v/v) tet system-approved fe-
tal bovine serum (Clontech Laboratories, Inc.), 1% (v/v)
Penicillin-Streptomycin (10 000 U/mL) (Life Technologies)
at 37◦C in 5% CO2. Hypoxanthine phosphoribosyltrans-
ferase (HPRT)-deficient Chinese hamster ovary (CHO) cells
(JCRB0218) were maintained in Ham’s F-12 nutrient mix-
ture (Invitrogen) plus 10% FBS, 1% P/S and 8 g/ml of
BS. HeLa cells were cultured inDulbecco’s modified Eagle’s
medium (DMEM; Invitrogen, Carlsbad, CA, USA) supple-
mented with 10% fetal bovine serum (FBS; Atlanta Bio-
logicals, Lawrenceville, GA, USA), 1% penicillin–strepto-
mycin (P/S; Invitrogen, USA) with 2 g/ml of Blasti-
cidin S (BS; Invitrogen) at 37◦C in 5% CO2. After load-
ing of tTAVP64 -containing plasmids into the loxP site of the
alphoidtetO-HAC, the HT1080 and CHO cells were cultured
in 1× HAT medium, 2 g/ml Blasticidin S and 1 g/ml
doxycycline (Life Technologies).
Loading of the tTA -containing plasmids into the loxP site of
the alphoidtetO-HAC
A total of 1–3 g of the tTAVP64 - or TAVP16 -containing
construct DNA and 0.8–1 g of the Cre expression pCpG-
iCre vector DNA were co-transformed with 6 l of X-
tremeGENE 9 DNA transfection reagent (Roche) into
HPRT-deficient human HT1080 and hamster CHO cells
containing the alphoidtetO-HAC that were grown on a 6 well
plate with DMEM, 10% FBS, 1% PenStrep, 2 g/ml Blas-
ticidin S (Life Technology) and 1 g/ml doxycycline (Life
Technology). HPRT-positive colonies were selected after 2–
3 weeks growth in HAT medium. 5–7 clones were then se-
lected in each experiment. Correct loading of the transgene
cassette into the HACwas confirmed by genomic PCRwith
a specific pair of primers that diagnose reconstitution of the
HPRT gene (Supplementary Table S1).
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FISH analysis with a BAC probe
FISH analysis was performed as previously described
(29,40). HAC-containing cells were cultured in medium
with 10 g/ml of colcemid (Invitrogen) for 3 h at 37◦C.
Metaphase cells were trypsinized and collected by centrifu-
gation for 5 min at 483 x g, treated in hypotonic solution
50 mM KCl for 20 min at 37◦C and washed three times in
10 ml of methanol:acetic acid (3:1) fixative solution. Cells
were centrifuged at 174 x g for 5 min between washes. Cells
were then diluted to the appropriate density with fixative
solution, spread onto precleaned slides (Fisher Scientific)
above steam (boiling water), and allowed to age 2 days at
room temperature. Metaphase chromosomes on the slide
were denatured by 70% formamide/2 x SSC for 2 min at
72◦C. Samples were dehydrated through a 70%, 90% and
100% ethanol series for 4 min each and left to air-dry. Or-
ange 552 dUTP (5-TAMRA-dUTP) (AbbottMolecular) la-
beled probes were denatured in hybridization solution at
78◦C for 10 min and left at 37◦C for 30 min. The hybridiza-
tion mix probe was applied to the sample and incubated at
37◦C overnight. Slides were washed with 0.4 x SSC, 0.3%
Tween 20 for 2min at 72◦C, briefly rinsedwith 2 x SSC, 0.1%
Tween 20 (5s-1min) and air dried in darkness. The samples
were counterstained with VectaShield mounting medium
with DAPI (Vector Labs). Slides were analyzed by fluores-
cence microscopy. Images were captured using a DeltaVi-
sionmicroscopy imaging system in the CRC, LRBGEFluo-
rescence Imaging Facility (NIH) and analyzed using image
J software (NIH). The probe used for FISH was BAC32–
2-mer(tetO) DNA containing a 40 kb of alphoid-tetO array
cloned into a BAC vector as described previously (29). BAC
DNA was labeled using a nick-translation kit with Orange
552 dUTP (5-TAMRA-dUTP) (Abbott Molecular).
Analysis of HAC mitotic stability by FISH
Fluorescence images of human cells carrying the HACwith
the tTAVP64 -containing cassette were analyzed. Cells were
processed for fluorescence in situ hybridization (FISH) us-
ing the BAC32-2-mer(tetO) DNA probe after 3, 4, 7 or 14
days of culturing without HAT selection in the presence or
absence of doxycycline. Metaphase spreads were screened
for the presence or absence of the HAC. At least 60–140
metaphases were screened for each clone. The stability of
the HAC was calculated as the percentage of alphoidtetO-
HAC-containing metaphase spreads in the absence or pres-
ence of doxycycline.
Reverse-transcriptase polymerase chain reaction
The alphoidtetO non-coding transcripts were detected in
HPRT-deficient HT1080 cells containing alphoidtetO-HAC
by RT-PCR using specific primers listed in Supplementary
Table S1. Total RNA was extracted using TRIzol reagent
(Invitrogen) according to the manufacturer’s instructions.
A measure of 2 g RNA was subsequently used for RT
with random hexamer primers, using the Roche Transcrip-
tor High Fidelity cDNA Synthesis Kit. Real-time PCR
analysis of cDNA equivalent to ∼70 ng (alphoidtetO) in-
put RNA was then performed using a SYBR Green Mas-
termix (JumpStart, Sigma) on a LightCycler480 system
(Roche). Oligonucleotide primer pairs are tetO-F/tetO-R2
(Supplementary Table S1) for the alphoidtetO non-coding
transcripts and actin-F/actin-R (Supplementary Table S1)
for control -actin transcripts. For each oligonucleotide
primer pair and every plate, a standard curve was created
using genomic DNA derived from the corresponding cell
line, thereby calculating the transcript copy numbers rel-
ative to the transcript copy number for the genomic lo-
cus. Background values (no reverse transcriptase) were sub-
tracted, and all values were normalized to -actin expres-
sion. For time course experiments, the transcript levels were
expressed relative to the dox+ values of the alphoidtetO,
which was arbitrarily set to 1. Similar conditions were used
to quantify transcription of the tTAVP64 from the HAC and
from transiently transfected tTAVP64 -containing plasmid
in human HT1080 cells. As a control, the level of tran-
scripts for the human GAPDH gene was measured. A list
of primers is presented in Supplementary Table S1.
Microcell-mediated chromosome transfer (MMCT)
The alphoidtetO HAC with the tTAVP64 -containing cassette
was transferred from hamster CHO to human epithelium
HeLa using a standard MMCT protocol (37,39). Micro-
cells were collected from about 1×108 CHO cells containing
the alphoidtetO-HAC carrying the tTAVP64 gene. HAC was
transferred into human HeLa cell line (3×106) via fusion
of microcells with target cells. For fusion we have used Neo
EX HVJ Envelope Transfection Kit (Cosmo Bio, Japan).
Blasticidin S (BS) was used to select resistant colonies. Blas-
ticidin S selection (4 g/ml) was applied 48 h later and
HeLa Blasticidin S resistant clones were picked after 2–3
weeks of growth under selective conditions. Typically 1–3
BSR colonies were obtained in one MMCT experiment in-
volving HAC transfer from hamster to human cells. Based
on FISH analysis, more than 95% of cells in the colony con-
tained a HAC.
ChIP assay and real-time PCR
ChIP with antibodies against trimethyl H3K4me3 (Up-
state) and CENP-A was carried out according to a pre-
viously described method (40). Briefly, cultured cells were
cross-linked in 1% formaldehyde for 10 min at 37◦C. Af-
ter addition of 1/10 volume of 1.25 M glycine and incu-
bation for 5 min, fixed cells were washed twice with cold
PBS buffer. Soluble chromatin was prepared by sonication
(Bioruptor sonicator; Cosmo Bio) to an average DNA size
of 500 bp in sonication buffer and immunoprecipitated in
IP buffer (20 mM Tris-HCl, pH 8.0, 600 mM NaCl, 1 mM
EDTA, 0.05% SDS, 1.0% Triton X-100, 20% glycerol, 1.5
M aprotinin, 10 M leupeptin, 1 mM DTT and 40 M
MG132). Protein G sepharose (Amersham, USA) blocked
with BSAwas added, and the antibody–chromatin complex
was recovered by centrifugation. The recovery ratio of the
immunoprecipitated DNA relative to input DNAwas mea-
sured by real-time PCR using a CFX96 real time PCR de-
tection system (Bio-Rad) and iQ SYBR Green Supermix
(Bio-Rad). Primers for alphoidtetO repeat (tetO) as well as
for control loci, 5S ribosomal DNA, are listed in Supple-
mentary Table S1. At least three independent ChIP experi-
ments were performed to estimate the level of enrichment.
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Statistical analysis
Statistical analysis was made using Prism (GraphPad Soft-
ware Inc., La Jolla, CA, USA). An unpaired Student t-test
was conducted to examine HAC stability upon binding of
tetR-VP64 to HAC alphoidtetO array induced by doxycy-
cline withdrawal. P < 0.05 was considered significant.
RESULTS
Construction of the tTAVP64- and tTAVP16- containing HACs
in HPRT-minus fibrosarcoma human HT1080 cells
The mega-size alphoid DNA array of the alphoidtetO-HAC
contains a unique loxP site combined with the 5’-end of
theHPRT sequence fragment such that gene loading events
can be selected by reconstitution of a functional HPRT
gene. The loxP-targeted region in theHACalso contains the
drug-resistance marker hygromycin (Hygro) and the thymi-
dine kinase gene of herpes simplex virus 1 (HS-tk) as well as
the Bsr gene (repeated ∼30–40 times within the mega-size
alphoid DNA array) (29,30,37).
In this study, two transcriptional transactivator tTA -
containing vectors, tetR-VP64-IRES-DsRed2 (Figure 1a;
Supplementary Figure S1) and tetR*-VP16-IRES-DsRed2
(Supplementary Figure S2a) were constructed (see Mate-
rials and Methods for details) and then inserted into the
loxP site of the alphoidtetO-HAC in HPRT-deficient human
HT1080 cells (Figure 1b) in order to determine the conse-
quences of a single copy tTA expression on HAC stability.
The tetR-VP64-IRES-DsRed2 vector contains the tTAVP64
sequence (four tandem repeats of theminimal VP16 domain
DALDDFDLDML fused with TetR), the color marker
DsRed2 and the 3’-end HPRT sequence fragment. The
tTAVP64 and DsRed2 sequences are transcribed from the
same CAG promoter but are separated by an internal ri-
bosome entry site (IRES) sequence (Figure 1a). Therefore,
while the tetR-VP64-IRES-DsRed2 vector encodes a sin-
gle tTAVP64/DsRed2 transcript it is translated into two pro-
teins: tTAVP64 (which binds to the multiple tetO-sequences
in the alphoid array of the HAC) and DsRed2 (which is
translated from IRES at a lower efficiency). The cHS4 in-
sulator flanks the whole cassette. The tetR*-VP16-IRES-
DsRed2 vector is identical to tetR-VP64-IRES-DsRed2 but
contains only one copy of the VP16 domain. The tTAVP64
or tTAVP16 binding to tetO sequences is negatively regulated
by doxycycline.
For insertion into the HAC, each vector was co-
transformed along with the Cre-recombinase expres-
sion vector into HPRT-minus HT1080 cells carrying the
alphoidtetO-HAC (Figure 1b). After insertion of the vector
into the HAC theHPRT gene was reconstituted (Figure 1d)
and the order and orientation of the transgenes is as shown
in Figure 1c. The efficiency of gene loading into the HAC
in HPRT-minus HT1080 cells was 1–2 × 10−4. From four
to six recombinant clones were selected by growth on HAT
medium after 12–15 days for each vector. All clones were se-
lected in the presence of doxycycline to prevent tTA binding
to the alphoidtetO array. Fluorescence microscopy revealed
expression of the DsRed2 transgene in all analyzed clones.
The presence of the autonomous form of the HACs carry-
ing the tTAVP64 or tTAVP16 cassette was examined by FISH
analysis. A fluorescence in situ hybridization image of one
representative clone with the tTAVP64 cassette is shown in
Figure 1e–g and with the tTAVP16 cassette in Supplemen-
tary Figure S2b. As seen, the HACs are maintained au-
tonomously. These clones were used for further analysis.
One copy of the transcriptional transactivator tTAVP64 within
alphoidtetO-HAC is enough to inactivate HAC kinetochore
To evaluate the effect of a single copy of the tTA on
HAC stability, cells bearing HACs carrying the tetR*-
VP16-IRES-DsRed2 or tetR-VP64-IRES-DsRed2 con-
structs were transferred into non-selective medium (HAT−
and BS−) either with doxycycline (dox+) to inhibit bind-
ing of the tTA to the alphoidtetO array sequence or with-
out doxycycline (dox−) to permit tTA binding. Cells were
cultured in these media for different time intervals. Then a
fluorescence image and FISH analysis with the probe spe-
cific for the alphoidtetO-HACwere carried out (seeMaterials
andMethods). For each HAC-containing clone at least 70–
80 metaphases were examined. No significant difference in
the mitotic stability of the HAC carrying the tTAVP16 cas-
sette was observed when cells were grown in dox+ or dox−
medium (Supplementary Figure S2c), indicating that the
cassette with one copy of the VP16 domain cannot inacti-
vate the HAC kinetochore. Note that it has been previously
shown that the same tTAVP16 cassette expressed from the
virus or plasmid-based multiple copy vector caused loss of
the alphoidtetO-HAC (29,37,39).
In contrast, a dramatic alphoidtetO HAC loss was ob-
served in dox− medium when the tTAVP64 cassette was in-
serted into the HAC. Data on FISH analysis presented as a
percentage of HAC-containing metaphases in different me-
dia (dox+ versus dox−) are summarized in Table 1. As seen,
the absence or presence of doxycycline had essentially little,
if any, effect on stability of the HAC after 3 days of cul-
ture. However, after 14 days, expression of the tTAVP64 fu-
sion protein caused a dramatic increase in the population
of cells lacking the HAC when the cells were grown in the
absence of doxycycline (dox−). As a consequence, a disap-
pearance of the DsRed2 fluorescence signal expressed from
the HAC was observed when the cells were grown in the ab-
sence of doxycycline (Figure 2a and b).Note that expression
of a single copy tTAVP64 from the HAC is 57-times lower
than expression of the same transgene from the multiple
copy vector transiently transfected into HT1080 cells (Sup-
plementary Figure S4). Differences between two analyzed
tTA cassettes is likely explained by a stronger effect of four
tandem repeats of the VP16 domain in tTAVP64 on chro-
matin status in the HAC kinetochore compared to tTAVP16.
Indeed, tTAVP64 was developed to increase the potency of
transcriptional activation of tTAVP16 (36).
Next, we examined the kinetics of HAC loss in one of
HT1080 clones after 3, 4, 7 and 14 days of culture in the
mediumwith andwithout doxycycline. As seen, the fraction
of cells carrying the HAC decreased dramatically in dox−
medium after 4 days of culture while remaining relatively
stable in dox+ medium (Figure 3).
Altogether, these data indicate that the expression of the
tTAVP64 consisting of four copies of VP16 loaded into the
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Figure 1. Loading of the tTAVP64-containing construct into the alphoidtetO-HAC propagated in human HPRT-minus HT1080 cells. (a) Diagram of the
construct tetR-VP64-IRES-DsRed2 used in this study. The construct contains a 3′ HPRT sequence and loxP site, the tTAVP64 (tetR with the VP64 carrying
four copies of VP16 activation domain) that is co-transcribed with theDsRed2 transgene under the sameCAG promoter. The cHS4 insulator (54) flanks the
expressing cassette from both sides. (A similar construct, tetR*-VP16-IRES-DsRed2, carrying one copy of the VP16 domain is described in Supplementary
Figure S2). Both constructs were inserted into the loxP site of the alphoidtetO-HAC propagated in HPRT-deficient HT1080 cells. (b) Loading of the vector
into the loxP site of the HAC is accompanied by reconstitution of the HPRT gene allowing cell selection on HAT medium. (c) A map of the resulting
transgene cluster in the HAC containing TK and Hygro genes, the DsRed2 color marker and the reconstructed HPRT gene. Arrows indicate direction of
transcription of the transgenes and 30–40 copies of BS incorporated in the alphoidtetO-HAC. (d) Lanes 1, 2 and 3 correspond to PCR products obtained
with the genomicDNA isolated fromHAC-containing clones of HT1080 cells using specific primers for theHPRT gene. The PCR products were sequenced
and confirmed reconstitution of the HPRT gene. M-ladder marker. (e–g) FISH analysis of the HAC-containing HT1080 clone. Chromosomal DNA was
counterstained with DAPI (blue) (e). The HAC was visualized using a BAC32–2-mer(tetO) probe (red) (f and g).
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Figure 2. (a) A scheme representing binding of tTAVP64 protein with the HAC followed by HAC loss from the cells as result of doxycycline removal. (b)
Bright and fluorescent images of one representative clone with the HAC carrying the tTAVP64-DsRed2 cassette cultured in dox+ medium and after removal
doxycycline followed by 14 days of culture. Cells were cultured without HAC selection (in HAT− and BS− medium). (c) Representative images of the
metaphase spread after 14 days of culture in the presence and absence of doxycycline. Chromosomal DNA was counterstained with DAPI (blue). The
HAC was visualized using a BAC32–2-mer(tetO) probe (red).
Table 1. Stability of the alphoidtetO-HAC/tTAVP64 in dox+ and dox− medium in human fibrosarcoma HT1080 cells
# clonea Medium 3 days 14 days
1 dox+ 99% 93%
dox− 90% 0%
2 dox+ 99% 92%
dox− 99% 0%
3 dox+ 80% 85%
dox− 75% 5%
4 dox+ 80% 72%
dox− 70% 1%
aFor each HAC-containing clone at least 70–80 metaphases were examined.
alphoidtetO-HAC induces HAC loss, presumably as a result
of changes in the HAC kinetochore chromatin.
Self-elimination of the alphoidtetO-HAC carrying the
tTAVP64 cassette is not cell line specific
Similar results on HAC self-elimination in dox− medium
were obtained in hamster ovarian CHO cells and in human
epithelial HeLa cells. For these experiments, the tetR-VP64-
IRES-DsRed2 construct was inserted into a single loxP site
of the alphoidtetO-HAC propagated in HPRT-minus ham-
ster CHO cells by Cre/loxP-mediated recombination (see
Materials and Methods) (Figure 4a). Several clones were
selected on HATmedium. Insertion into the HACwas con-
firmed by PCR using specific primers (Supplementary Ta-
ble S1). These primers were diagnostic for reconstitution
of the HPRT gene, which accompanies Cre/loxP target-
ing. A FISH image of one representative clone of the HAC
in CHO cells in dox+ medium after 14 days of culture is
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Figure 3. Kinetics of mitotic stability of the HAC carrying the construct
tetR-VP64-IRES-DsRed2. The cells were cultured under following condi-
tions: dox+ 3 days and dox− 3 days, dox+ 4 days and dox− 4 days, dox+
7 days and dox− 7 days, dox+ 14 days and dox− 14 days. To quantify the
HAC retention, the cells were analyzed by FISH. FISH analysis included
detection of the HAC on metaphase spreads. At least 70–80 metaphase
spreads were analyzed for each point. Addition of doxycycline, which pre-
vents fusion of the tetracycline repressor from binding to tetO sequences
of the HAC, blocks the inactivation of HAC kinetochore. Targeting the
transcriptional transactivator tTAVP64 into the HAC kinetochore in the
absence of doxycycline induces HAC loss.
shown in Figure 4b. This FISH confirmed that the HAC
is maintained autonomously. One CHO clone containing
alphoidtetO-HAC/tTAVP64 was chosen for transfer to hu-
manHeLa cells viaMMCT (Figure 4c). FISH analysis con-
firmed that the HAC propagates autonomously without de-
tectable integration into chromosomes (Figure 4d). The re-
sults on the HAC stability in twoHAC-containing clones in
CHO and HeLa cell lines in dox+ versus dox− medium are
summarized in Table 2. As seen, expression of the tTAVP64
cassette from the HAC induces a dramatic HAC loss in the
absence of doxycycline in the analyzed cell lines after 14
days of culture (Table 2; Figure 4b and d).
Chromatin changes in the alphoidtetO-HAC kinetochore in-
duced by tTAVP64 tethering
Previously we have demonstrated that expression of the
transcriptional activator (tTA) containing only one copy of
the minimal VP16 domain DALDDFDLDML from the vi-
ral vectors produced ‘open’ chromatin in the alphoidtetO-
HAC allied with a substantial elevation in transcripts spe-
cific for synthetic alphoid DNA array (29,31,34). Such a
high level of transcription of the alphoidtetO array resulted
in a rapid inactivation of the HAC kinetochore due not
only to a complete block of CENP-A loading, but also due
to stripping of pre-assembled CENP-A and other CCAN
(constitutive centromere-associated network) proteins from
the HAC kinetochore (32).
In this work, we examined whether a single copy of the
tTAVP64 incorporated into the alphoidtetO-HAC had a simi-
lar effect on the HAC centrochromatin as multiple copies of
the tTA expressed from a viral vector when a large amount
of the transcriptional activator is produced.
In our first experiments, the transcription of satellite
DNA in alphoidtetO array was found to be significantly in-
creased (3-fold) after 3 days of growth in the medium lack-
ing doxycycline in clone #1 [t-test, t(4) = 12.3554, P =
0.0002]. In clone #2, there was a significant increase (6-fold)
after 2 days [t-test, t(4) = 53.9038, P < 0.0001] that fur-
ther increased by 9-fold after 3 days [t-test, t(4) = 146.6633,
P < 0.0001] (Figure 5a and b). These experiments demon-
strate that targeting of HAC kinetochore chromatin by a
single expressed copy of the tTAVP64 leads to a significant in-
crease of transcription of non-coding alphoidtetO array after
3 days of cell growth (Figure 5a and b). These results corre-
late with ChIP data on enrichment of H3K4me3, a marker
for the 5’ end of actively transcribed genes (28,29,50,51), on
alphoidtetO array in the HAC. In two independent clones,
the HAC chromatin following tTAVP64 expression failed to
reveal significant structural differences after one day of cul-
ture in dox− medium but was significantly (3–4 fold) in-
creased on the alphoidtetO array of the HAC after 3 days of
culture in the medium lacking doxycycline [t(4) = 31.2421,
P < 0.0001 for clone #1 and t(4) = 49.8532, P < 0.0001 for
clone #2] (Figure 5c and d). Thus, elevation of satellite tran-
scription of the alphoidtetO array after 3 days was accompa-
nied by enrichment in H3K4me3 chromatin. No significant
difference in the level of CENP-A on the alphoidtetO array
was observed when cells were grown in the presence or ab-
sence of doxycycline after 3 days of culture [t(4) = 2.1625,
P = 0.0966] (Figure 5e). However, a longer culturing of the
cells in dox− medium (4, 8 and 12 days) resulted in a dra-
matic decrease of the level of CENP-A (Figure 5e) followed
by kinetochore inactivation and HAC loss (Figure 3) that
is in agreement with our previous results on inactivation of
the HAC kinetochore by tTA using viral vectors (29,31,32).
Development of a novel alphoidtetO-HAC/ tTAVP64-based
system to verify phenotypic changes attributed to expression
of HAC-encoded genes
The phenomenon of HAC loss caused by expression of the
tTAVP64-containing chromatin modifier from the HAC can
be used to develop a powerful system to verify phenotypes
induced by a gene(s) loaded into the single loxP site of
the alphoidtetO-HAC. This could be achieved by combin-
ing the TAR-cloning vector (43), used to selectively isolate
any full-length gene from multiple human genomes, with
the tTAVP64- containing modifier cassette followed by load-
ing of this final vector along with a gene of interest into the
HAC. Figure 6a shows a diagram of a newly constructed
TAR-BRV- tTAVP64 cloning vector (see details in Supple-
mentary Figure S5). This vector contains restriction sites
for insertion of two unique targeting sequences (hooks) (red
dots) homologous to the 5’ and 3’ ends of a gene of inter-
est and restriction sites for insertion of chromatin insula-
tors (green dots) (48), such as tRNA (52,53) or cHS4 (54)
or  -satellite DNA (55) to protect the captured gene from
silencing. The vector also contains a YAC cassette that in-
cludes theHIS3marker for selection in yeast and theCEN6
centromere for proper segregation in yeast cells as well as
a BAC cassette that includes the F’ factor origin of repli-
cation and the chloramphenicol acetyltransferase (CmR)
gene for selection in bacterial cells. This allows the TAR-
isolated gene to be isolated either directly from yeast (56) or
moved to bacterial cells without a step of YAC retrofitting
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Figure 4. The alphoidtetO-HAC/tTAVP64 in different cell lines. (a) Insertion of the construct tetR-VP64-IRES-DsRed2 into the loxP site of the alphoidtetO-
HAC propagated in HPRT-deficient hamster CHO cells by Cre/loxP mediated recombination. (b) FISH analysis of the hamster clone carrying the au-
tonomously propagated alphoidtetO-HAC/tTAVP64 in dox+ medium and after removal doxycycline followed by 14 days of culture. (c) From CHO cells the
alphoidtetO-HAC/tTAVP64 was MMCT-transferred to human HeLa cells. (d) FISH analysis of the HeLa human clone carrying the autonomously propa-
gated alphoidtetO-HAC/tTAVP64 in dox+ medium and after removal doxycycline followed by 14 days of culture. Chromosomal DNA was counterstained
with DAPI (blue). The HAC was visualized using a BAC32–2-mer(tetO) probe (green).
Table 2. Stability of the alphoidtetO-HAC/tTAVP64 in dox+ and dox− medium in hamster CHO and human HeLa cells
Hamster ovary CHO cells
# clonea Medium 3 days 14 days
1 dox+ 99% 77%
dox− 99% 4%
2 dox+ 99% 85%
dox− 99% 5%
Human epithelium HeLa cells
1 dox+ 99% 93%
dox− 99% 2%
2 dox+ 99% 92%
dox− 99% 3%
aFor each HAC-containing clone at least 130–140 metaphases were examined.
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Figure 5. Chromatin/transcription changes in the alphoidtetO-HAC kinetochore induced by tTAVP64 tethering. (a and b) De-repression of tetO-alpha-
satellite DNA transcription in the HAC when cells are grown in the medium lacking doxycycline. Quantitative RT-PCR experiments for two clones, clone
#1 and clone #2, showing that the transcripts of non-coding tetO-alpha-satellite DNA repeats in the alphoidtetO-HAC are significantly repressed in the cells
growing in doxycycline-containing medium compared to that of the cells that have been grown in the medium lacking doxycycline. (c and d) Chromatin
immunoprecipitation (ChIP) analysis of non-coding tetO-alpha-satellite DNA repeats in the alphoidtetO-HAC in two clones using antibodies against
H3K4me3 in the cells growing in doxycycline-containing medium compared to that of the cells that have been grown in the medium lacking doxycycline
after 1 and 3 days of culture. Data were normalized to the internal 5S rDNA controls. (e) ChIP analysis of CENP-A chromatin in the alphoidtetO-HAC in
the clone #2 cultured in the presence and absence of doxycycline for different time intervals (3, 4, 8 and 12 days of culture). Enrichment is shown relative
to the chromosome 21 centromere. Error bars indicate s.d. The significant differences were calculated using Student’s two-tailed t-test.
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Figure 6. (a) A scheme of the TAR-BRV- tTAVP64 vector. This vector contains restriction sites for insertion of two unique targeting sequences (hooks)
(dot red) homologous to 5’ and 3’ ends of a gene of interest and restriction sites for insertion of chromatin insulators to protect a gene from silencing
(dot green). The vector also contains a YAC cassette that includes a yeast selectable marker HIS3 for selection in yeast and a yeast centromere CEN6
for proper segregation in yeast cells. The TAR-BRV- tTAVP64 vector also contains a BAC cassette that includes a F’ factor origin of replication and the
chloramphenicol acetyltransferase (CmR) gene for selection in bacterial cells. For gene TAR cloning experiments, the TAR-BRV- tTAVP64 vector DNA
should be linearized by a unique endonuclease located between the hooks to expose targeting sequences (hooks). The TAR-BRV- tTAVP64 vector also
contains a 3’ HPRT-loxP cassette allowing a further loading of a TAR-gene isolate into the unique loxP site of the alphoidtetO-HAC in hamster CHO cells
by Cre/loxP mediated recombination, from where the HACmay beMMCT-transferred to the recipient human cells for further gene function analysis. The
TAR-BRV- tTAVP64 vector also contains the tTAVP64 chromatin modifier that is constitutively expressed from the HAC. In the presence of doxycycline the
tTAVP64 cannot bind to the tetO-sequences in the alphoidtetO-HAC. (b) FISH analysis of the HAC containing the TAR-BRV- tTAVP64 vector in HT1080
cells. Chromosomal DNA was counterstained with DAPI (blue). The HAC was visualized using a vector probe (red).
with BAC sequence (39) for further gene DNA isolation.
The TAR-BRV- tTAVP64 vector also contains a 3’ HPRT-
loxP cassette allowing further loading of the TAR-gene iso-
late into the unique loxP site of the alphoidtetO-HAC gene
delivery vector in hamster HPRT-deficient CHO cells by
Cre/loxP mediated recombination. From there the HAC
may be MMCT-transferred (37,57) to the recipient human
cells for further gene function analysis (23,38,39). Impor-
tantly, because the TAR-BRV- tTAVP64 vector contains the
chromatin modifier that is constitutively expressed from the
HAC, integrity of the HAC kinetochore and, as a conse-
quence, expression of a gene of interest in the cells can be
regulated. In the presence of doxycycline when the tTAVP64
does not bind to the tetO-sequences in the alphoidtetO-
HAC, the HAC is mitotically stable and each cell contains
a product of a gene loaded into the HAC. After removal of
the ligand doxycycline, the tTAVP64 binds to tetO-sequences
of the HAC resulting in HAC loss along with a gene of in-
terest.
As a proof of principle, the TAR-BRV- tTAVP64 vector
was inserted into the loxP site of the alphoidtetO-HAC in
humanHPRT-deficientHT1080 cells. FISHanalysis proved
that the HAC is maintained in the autonomous form (Fig-
ure 6b). Three randomly chosen clones were analyzed in
dox+ and dox− media with the following FISH analysis to
confirm HAC loss in the medium lacking doxycycline. To
protect the tTAVP64 expression from silencing, the tRNA in-
sulator (52) was inserted upstream of the CAG promoter.
Significant HAC loss was observed in three out of three se-
lected clones cultured in the absence of doxycycline after 16
days of culture (Table 3). The greater HAC loss observed for
the original tetR-VP64-IRES-DsRed2 vector may be due to
the difference either in the structure of the cassettes or the
insulator type used (cHS4 vs tRNA) (52–54). It is known
that different insulator types have a different level of gene
protection (48).
To summarize, the TAR-BRV-tTAVP64 gene cloning vec-
tor allows to control expression of genes loaded into the
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Table 3. Stability of the alphoidtetO-HAC/TAR-BRV- tTAVP64 in dox+ and dox− medium in HT1080 cells
# clonea Medium 2 days 16 days
1 dox+ 96% 73%
dox− 80% 8%
2 dox+ 98% 75%
dox− 84% 8%
3 dox+ 98% 72%
dox− 79% 7%
aFor each HAC-containing clone at least 70–90 metaphases were examined.
alphoidtetO-HAC by simple removal of a ligand (doxycy-
cline) that results in the kinetochore disassembly followed
by the HAC loss.
DISCUSSION
The alphoidtetO-HAC is an advancedHAC-based vector for
gene delivery and regulated gene expression (23,29,37,39).
This HAC consists of a megabase-size synthetic, higher or-
der alpha-satellite repeat array with a tet operator sequence
(tetO) in every other alphoid monomer. This provides a sig-
nificant advantage for this HAC compared to other HAC-
based vectors because its kinetochore can be inactivated
by tethering the tTS silencer or the tTA transcriptional
transactivator or other chromatin modifiers to the tetO se-
quences leading to HAC loss (29,31,32,34,37). This HAC
feature provides a control for phenotypes induced by test
genes loaded into the alphoidtetO-HAC.
In our previous studies, induction of alphoidtetO-HAC
loss was initiated by transfection of cells by viral or plasmid
vectors expressing multiple copies of a chromatin modifier,
a step that is potentially mutagenic (23,29,37,39). Recently
we described a re-engineered alphoidtetO-HAC that allows
verification of phenotypic changes attributed to expression
of genes from the HAC without the potentially mutagenic
transfection step (40). In that HAC, a single copy of the
tTS was inserted into a unique gene-loading site along with
a gene of interest. Expression of the tTS generated a self-
regulating fluctuating heterochromatin on the alphoidtetO-
HAC that induced a fast silencing of the gene on the HAC
without significant effects onHAC segregation (40). Impor-
tantly, inactivation of a gene on the alphoidtetO-HAC/tTS
was reversible by addition of doxycycline, presumably be-
cause the tTS was silencing its own expression. Thus, ex-
pression of a single auto-regulated copy of the tTS from the
alphoidtetO-HAC provides an efficient method to switch off
or switch on expression of the gene(s) loaded onto theHAC.
In this work, we engineered the novel alphoidtetO-HAC/
tTAVP64 and demonstrated that a single copy of the tran-
scriptional transactivator tTAVP64 constitutively expressed
from the HAC also allows a stable expression of the HAC
gene(s) in the presence of doxycycline. In contrast to the
alphoidtetO-HAC/tTS, culturing of the alphoidtetO-HAC/
tTAVP64 in mediumwithout doxycycline induces a fast inac-
tivation of the HAC kinetochore leading to HAC loss along
with a loaded gene. The different effect of tTS and tTAVP64
on the HAC kinetochore function is presumably due to
that the tTAVP64 does not self-silence. This provides a pure
control for phenotypic changes attributed to expression of
a HAC-encoded gene by returning the mutant cell line to
its original state following removal of the HAC from the
cell. The alphoidtetO-HAC/ tTAVP64 with a regulated kine-
tochore may have a specific application for generation of in-
duced pluripotent stem (iPS) cells for regenerativemedicine.
It is worth noting that recent publications demonstrate the
use of other HAC vectors for reprogramming mouse em-
bryonic fibroblasts (MEFs) into induced iPS cells (5,6).
In addition, in this work we combined the alphoidtetO-
HAC-based gene delivery vector with TAR gene-cloning
technology and demonstrated a potential to carry out a
complete cycle starting with selective gene isolation us-
ing a newly constructed TAR cloning vector, TAR-BRV-
tTAVP64, followed by tTAVP64 and a gene of interest expres-
sion from theHAC vector and ended by theHAC loss along
with a gene. This new vector contains a BAC cassette and,
therefore, allows the direct transfer of TAR-isolated genes
from yeast to bacterial cells for further BAC DNA isola-
tion. This vector also contains a 3’HPRT-loxP cassette al-
lowing direct gene loading into the alphoidtetO-HAC for the
following complementation of gene deficiencies in human
cells. The gene expression from the alphoidtetO-HAC can
be eliminated by a simple removal of doxycycline from the
medium because tTAVP64 is inserted along with a gene of in-
terest into the HAC. A hypothetical scheme illustrating the
entire process, starting with TAR isolation of a gene from
genomic DNA in yeast using a TAR-BRV- tTAVP64 vector
then proceeding to its direct transfer to bacterial cells and
subsequent insertion into the alphoidtetO-HAC and end-
ing with the verification of gene-induced phenotypes by in-
ducing HAC loss, is diagrammed in Supplementary Fig-
ure S6. It is worth noting that a YAC/BAC/TAR gene-
containing construct could also possibly be introduced into
HAC-containing human cells through yeast spheroplast fu-
sion to human cells (58).
Thus, we have designed two approaches to verify gene-
induced phenotypes using HAC vectors. In the first case,
when a single copy of tTS is expressed, a self-regulating
fluctuating heterochromatin is generated on the alphoidtetO-
HAC. This can induce a fast silencing of the gene(s) on
the HAC without significant effects on HAC stability and
such gene silencing is reversible by addition of doxycycline
(40). In the second case, expression of a single copy of the
tTAVP64 from the HAC induces a fast inactivation of the
HAC kinetochore leading to irreversible HAC loss along
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with the loaded gene. Both approaches are useful for stud-
ies of gene function and have a potential for cell and gene
therapy.
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